右美托咪定治疗大麻戒断综合征延迟高峰症状：一例报告
Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report.
作者信息
MacCamy Katie, Hu Daniel
机构信息
College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Providence St. Peter Hospital, Olympia, WA, USA.
出版信息
Hosp Pharm. 2021 Oct;56(5):462-465. doi: 10.1177/0018578720919025. Epub 2020 May 13.
Abstract
Cannabis withdrawal syndrome (CWS) is characterized by irritability, sleep disorders, and physical discomfort that typically peaks within 7 days of cessation. A patient with a 30-year history of heavy cannabis developed prolonged symptoms of CWS that peaked at greater than 40 days after cessation, who was successfully managed with dexmedetomidine. This case report documents an unusual case of significantly delayed CWS peak in symptoms, as well as the novel use of dexmedetomidine for inpatient management of CWS.
摘要
大麻戒断综合征（CWS）的特征是易怒、睡眠障碍和身体不适，这些症状通常在停止使用大麻后7天内达到峰值。一名有30年大量使用大麻史的患者出现了CWS的延长症状，在停止使用大麻后40多天达到峰值，该患者通过右美托咪定成功得到治疗。本病例报告记录了一例症状峰值明显延迟的CWS罕见病例，以及右美托咪定在CWS住院治疗中的新应用。
相似文献
1
Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report.右美托咪定治疗大麻戒断综合征延迟高峰症状：一例报告
Hosp Pharm. 2021 Oct;56(5):462-465. doi: 10.1177/0018578720919025. Epub 2020 May 13.
2
Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis.经常或依赖使用大麻素人群中出现大麻戒断症状的流行率：系统评价和荟萃分析。
JAMA Netw Open. 2020 Apr 1;3(4):e202370. doi: 10.1001/jamanetworkopen.2020.2370.
3
Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients.青少年和年轻成人大麻依赖住院患者的大麻戒断严重程度和短期病程。
Drug Alcohol Depend. 2010 Jan 15;106(2-3):133-41. doi: 10.1016/j.drugalcdep.2009.08.008. Epub 2009 Sep 23.
4
The cannabis withdrawal syndrome: current insights.大麻戒断综合征：当前见解
Subst Abuse Rehabil. 2017 Apr 27;8:9-37. doi: 10.2147/SAR.S109576. eCollection 2017.
5
DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults.DSM-5 大麻戒断综合征：美国成年人的人口统计学和临床相关性。
Drug Alcohol Depend. 2019 Feb 1;195:170-177. doi: 10.1016/j.drugalcdep.2018.09.005. Epub 2018 Oct 22.
6
Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum.在住院戒毒期间对慢性大麻成瘾者进行前瞻性监测的戒断现象：大麻戒断综合征及其与血清中Δ-9-四氢大麻酚及其代谢产物的相关性。
Drug Alcohol Depend. 2014 Oct 1;143:189-97. doi: 10.1016/j.drugalcdep.2014.07.027. Epub 2014 Aug 1.
7
Sleep disturbance after cessation of cannabis administration in mice.小鼠停止大麻给药后的睡眠障碍。
Neuropsychopharmacol Rep. 2023 Dec;43(4):505-512. doi: 10.1002/npr2.12329. Epub 2023 Mar 11.
8
Cannabis withdrawal induced brief psychotic disorder: a case study during the national lockdown secondary to the COVID-19 pandemic.大麻戒断引起的短暂精神病性障碍：COVID-19 大流行期间全国封锁期间的病例研究。
J Addict Dis. 2021 Oct-Dec;39(4):579-584. doi: 10.1080/10550887.2021.1910473. Epub 2021 Apr 22.
9
[Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence].[仅大麻依赖患者以及大麻和阿片类物质依赖患者中的大麻戒断综合征]
Encephale. 2011 Sep;37(4):266-72. doi: 10.1016/j.encep.2010.12.007. Epub 2011 Feb 5.
10
Cannabis withdrawal syndrome: An important diagnostic consideration in adolescents presenting with disordered eating.大麻戒断综合征：青少年出现饮食失调时需要考虑的重要诊断因素。
Int J Eat Disord. 2014 Mar;47(2):219-23. doi: 10.1002/eat.22229. Epub 2013 Nov 26.
引用本文的文献
1
Psychosis associated with cannabis withdrawal: systematic review and case series.与大麻戒断相关的精神病：系统评价与病例系列
Br J Psychiatry. 2024 Dec 3:1-12. doi: 10.1192/bjp.2024.175.
2
Considerations for Cannabinoids in Perioperative Care by Anesthesiologists.麻醉医生在围手术期护理中对大麻素的考量
J Clin Med. 2022 Jan 22;11(3):558. doi: 10.3390/jcm11030558.
3
Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?通过商业即时检验半定量免疫测定法测量的尿大麻素水平能否预测大麻戒断综合征的严重程度？
Front Psychiatry. 2020 Dec 3;11:598150. doi: 10.3389/fpsyt.2020.598150. eCollection 2020.
本文引用的文献
1
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.大麻药物相互作用基础：促进剂、药理学和药代动力学。
Pharmacol Ther. 2019 Sep;201:25-38. doi: 10.1016/j.pharmthera.2019.05.001. Epub 2019 May 7.
2
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.大麻戒断症状的大麻素激动剂替代疗法疗效的系统评价。
CNS Drugs. 2018 Dec;32(12):1113-1129. doi: 10.1007/s40263-018-0577-6.
3
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.大麻使用障碍和戒断的药物治疗现状。
Neuropsychopharmacology. 2018 Jan;43(1):173-194. doi: 10.1038/npp.2017.212. Epub 2017 Sep 6.
4
The cannabis withdrawal syndrome: current insights.大麻戒断综合征：当前见解
Subst Abuse Rehabil. 2017 Apr 27;8:9-37. doi: 10.2147/SAR.S109576. eCollection 2017.
5
Cannabis, Cannabinoids, and Sleep: a Review of the Literature.大麻、大麻素与睡眠：文献综述。
Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9.
6
Use of dexmedetomidine to treat delirium primarily caused by cannabis.使用右美托咪定治疗主要由大麻引起的谵妄。
Am J Emerg Med. 2017 Mar;35(3):524.e1-524.e2. doi: 10.1016/j.ajem.2016.10.027. Epub 2016 Oct 11.
7
A cannabinoid-intoxicated child treated with dexmedetomidine: a case report.一名使用右美托咪定治疗的大麻素中毒儿童：病例报告。
J Med Case Rep. 2015 Jul 3;9:152. doi: 10.1186/s13256-015-0636-2.
8
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.纳布啡醇作为大麻戒断期的激动剂替代治疗：一项随机临床试验。
JAMA Psychiatry. 2014 Mar;71(3):281-91. doi: 10.1001/jamapsychiatry.2013.3947.
9
Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers.DSM-5 大麻戒断症状在多药物滥用者中的时间进程。
BMC Psychiatry. 2013 Oct 12;13:258. doi: 10.1186/1471-244X-13-258.
10
The cannabis withdrawal syndrome.大麻戒断综合征。
Curr Opin Psychiatry. 2006 May;19(3):233-8. doi: 10.1097/01.yco.0000218592.00689.e5.
Zotero 插件